
CMX990 is a novel covalent SARS-CoV-2 3CL protease ингибитор with EC50 of 10 nM, and shows good oral bioavailability and tolerability in preclinical species. Compared with nirmatrelvir, CMX990 has distinctly differentiated potency (~5-fold more мощный in primary cells) and human in vitro clearance (>4-fold better microsomal clearance and >10-fold better hepatocyte clearance), with good in vitro-to-in vivo correlation.
CMX990 is a novel covalent SARS-CoV-2 3CL protease inhibitor with EC50 of 10 nM, and shows good oral bioavailability and tolerability in preclinical species. Compared with nirmatrelvir, CMX990 has distinctly differentiated potency (~5-fold more potent in primary cells) and human in vitro clearance (>4-fold better microsomal clearance and >10-fold better hepatocyte clearance), with good in vitro-to-in vivo correlation.
Вращайте мышью · Колесо — масштаб
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.